#MedicalTechnology #Stock Sigyn Therapeutics (OTC: $SIGY) Reports Results of Pilot Study to Address Inflammatory CytoVesicles; @Sigyn_inc
Sigyn Therapy™ is a Candidate to Treat Life-Threatening
Inflammatory Conditions That Are Not Addressed with Drug Therapies
SAN DIEGO CA, January 6, 2021 -- (Investorideas.com Newswire) Medical Therapeutic technology stock news - Sigyn Therapeutics, Inc. (OTCMarkets: SIGY) , a medical technology company whose focus is the treatment of life-threatening inflammatory conditions precipitated by Cytokine Storm Syndrome (the Cytokine Storm), today announced the results of an in vitro pilot study that successfully modeled the ability of Sigyn Therapy™ to address CytoVesicles that transport inflammatory cytokine cargos in the bloodstream.
Read this news, featuring SIGY in full at https://www.investorideas.com/news/2021/biotech/01061SIGY-Inflammatory-CytoVesicles.asp
Cytokine Storm Syndrome is an excessive
response of the immune system that is induced by infectious and non-infectious
conditions. A hallmark indicator of Cytokine Storm Syndrome is the excessive or
uncontrolled release of pro-inflammatory cytokines, which can lead to multiple
organ failure and cause death. The
annual market opportunity to address Cytokine Storm related indications exceeds
$20 billion and includes sepsis, the most common cause of hospital deaths worldwide. Virus-induced Cytokine Storm Syndrome is a
leading cause of death resulting from severe SARS-CoV-2 (COVID-19) infections.
Sigyn Therapy is a proprietary blood
purification technology designed to overcome the limitations of previous drug
and device candidates to treat acute inflammatory conditions. Incorporated within Sigyn Therapy is a
cocktail of adsorbent components with unique binding and capture
characteristics to optimize the broad-spectrum depletion of inflammatory targets
from the bloodstream. These targets include pro-inflammatory cytokines,
endotoxin and CytoVesicles (extracellular vesicles that transport inflammatory
cytokine cargos) that participate in concert with freely circulating cytokines
to further escalate the Cytokine Storm. CytoVesicles are an important yet previously elusive
target as they can be 20-60 times larger than cytokines themselves.
In the in vitro pilot study, 104nm liposomes
were utilized as a model system to assess the ability of Sigyn Therapy’s
adsorbent components to deplete CytoVesicles from human blood plasma. After a two-hour interaction with Sigyn’s
adsorbent components, liposome concentrations in human blood plasma were
reduced ~90%. Previously published
studies have validated liposomes as a model for the isolation of extracellular vesicles from blood based on the
similarity of their size and structural characteristics.
“When we designed Sigyn Therapy, we
envisioned a device that could be broadly deployed by the medical community,
yet also have expansive first-in-industry capabilities that offer to improve
patient outcomes,” stated Jim Joyce, Chairman and CEO of Sigyn Therapeutics. “When
considering our previous report that Sigyn Therapy™ clears both endotoxin and
inflammatory cytokines from human blood plasma, the observation from our
CytoVesicle pilot study further reinforces the potential for our vision to
become a therapeutic reality.”
Sigyn Therapy is a single-use device designed
for use on the established infrastructure of dialysis and CRRT machines already
located in hospitals and clinics worldwide. On December 1, 2020, the Company reported the results of
an in vitro study that validated the ability of Sigyn Therapy to simultaneously
reduce the presence of endotoxin and relevant pro-inflammatory cytokines, which
included Interleukin-1 Beta (IL-1B), Interleukin-6 (IL-6) and Tumor Necrosis Factor
alpha (TNF-a). Endotoxin (lipopolysaccharide or LPS) is a potent mediator
implicated in the pathogenesis of sepsis and septic shock. The dysregulated over-production of IL-1B,
IL-6 and TNF-a can lead to organ failure and cause death.
An objective of the study was to rebalance
elevated cytokine levels and optimize the elimination of endotoxin from human
blood plasma. The study was conducted in triplicate over four-hour time periods
with a pediatric version of Sigyn Therapy.
Average reduction of endotoxin load peaked at 83% during the studies. The
average reduction of IL-1B was 69%, IL-6 reduction was 59% and TNF-a reduction was
57% during the four-hour studies.
The resulting data from each of these studies
will be incorporated into an Investigational Device Exemption (IDE) that Sigyn
Therapeutics plans to submit to the United States Food and Drug Administration
(FDA) in 2021.
About Sigyn Therapeutics
Sigyn Therapeutics™ is a development-stage
therapeutic technology company headquartered in San Diego, California USA. Our
focus is directed toward a significant unmet need in global health; the
treatment of life-threatening inflammatory conditions that are precipitated by Cytokine
Storm Syndrome and not addressed with an approved therapy. Our mission is to
save lives.
Sigyn Therapy™ is a novel blood purification
technology designed to mitigate cytokine storm syndrome through the
broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine
storm syndrome is the hallmark of sepsis, which is the most common cause of
in-hospital deaths and claims more lives each year than all forms of cancer
combined. Virus induced cytokine storm (VICS) is associated with high mortality
and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic
opportunities include, but are not limited to bacteria induced cytokine storm
(BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver
failure, such as hepatic encephalopathy.
To learn more, visit www.SigynTherapeutics.com or www.SigynTherapy.com
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking
statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks
and uncertainties. All statements contained in this press release are
forward-looking statements within the meaning of The Private Securities
Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,”
“anticipate,” “approximate,” “expect,” “potential,” or the negative of these
terms or other similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these
identifying words. These forward-looking statements include, among others,
statements about Sigyn’s future financial performance, the impact of management
changes, any proposed organizational restructuring, results of operations,
capital resources to fund operations; statements about Sigyn’s expectations
regarding the capitalization, resources and ownership structure of the combined
company; statements about the potential benefits of the transaction; the expected
completion and timing of the transaction and other information relating to the
transaction; and any other statements other than statements of historical fact.
Actual results or events could differ materially from the plans, intentions and
expectations disclosed in the forward-looking statements that Sigyn makes due
to a number of important factors, including (i) the risk that the transaction
may not be completed in a timely manner or at all, which may adversely affect
Sigyn’s business and the price of the common stock of Sigyn, (ii) the failure
to satisfy of the conditions to the consummation of the transaction, (iii) the
occurrence of any event, change or other circumstance that could give rise to
the termination of the merger agreement, (iv) risks related to the ability to
realize the anticipated benefits of the transaction, including the risk that
the businesses will not be integrated successfully, (v) the effect of the
announcement or pendency of the transaction on Sigyn’s business relationships,
operating results and business generally, (vi) risks that the proposed
transaction disrupts current plans and operations, (vii) risks related to the
combined entity’s ability to up-list to a national securities exchange, (viii)
risks related to the combined entity’s access to existing capital and
fundraising prospects to fund its ongoing operations, (ix) risks related to
diverting management’s attention from Sigyn’s ongoing business operations, (x)
other business effects, including the effects of industry, market, economic,
political or regulatory conditions, future exchange and interest rates, and
changes in tax and other laws, regulations, rates and policies, and (xi) risks
related to an inability to manufacture Sigyn Therapy, risks related to the
clinical advancement of Sigyn Therapy with regulatory agencies, and no
assurance that Sigyn Therapy will be proven to be a safe and efficacious treatment
for any condition. The forward-looking statements in this press release
represent Sigyn’s views as of the date of this press release. Sigyn anticipates
that subsequent events and developments may cause its views to change. However,
while it may elect to update these forward-looking statements at some point in
the future, it specifically disclaims any obligation to do so. You should,
therefore, not rely on these forward-looking statements as representing Sigyn’s
views as of any date subsequent to the date of this press release.
Contact Sigyn Therapeutics, Inc.
Jim Joyce
Chairman, CEO
(619) 368-2000
Paid News -Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party
sourced news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investment involves risk and
possible loss of investment. This site is currently compensated for news
publication and distribution, social media and marketing, content creation and
more. Contact each company directly regarding content and press release
questions. Disclosure is posted for each compensated news release, content
published /created if required but otherwise the news was not compensated for
and was published for the sole interest of our readers and followers.
Disclosure : this news release featuring Sigyn Therapeutics, Inc. (OTCMarkets:
SIGY), is a paid for service on
Investorideas.com . More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com lease read Investorideas.com
privacy policy https://www.investorideas.com/About/Private_Policy.asp
About Investorideas.com
https://www.investorideas.com/About/
Sign up for free stock news alerts at
Investorideas.com
https://www.investorideas.com/Resources/Newsletter.asp
BiotechIndustryStocks.com
- investing ideas in biotechnology stocks, medical technology and life sciences
Like Biotech Stocks? View our Biotech
Stocks Directory
Get News
Alerts on Biotech Stocks
